AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$LQDA

Saggar Rajeev sold $263K of LQDA

Saggar Rajeev (Chief Medical Officer) sold 9,218 shares of Liquidia Corp (LQDA) at $28.48 ($0.26M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Saggar Rajeev
Published Oct 14, 2026, 12:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The disclosed sale adds a data point for investors monitoring insider activity but is unlikely to move the stock significantly.

02

Market read

Provides a fresh insider transaction record; modest relevance for short-term traders.

03

What to watch

The 10b5-1 plan suggests pre-scheduled execution, reducing the informational content of the trade.

Relevance 3/10Novelty 3/10Timing: post-market filing

Background

SEC Form 4 filings disclose insider transactions; this filing reports a sale by the company's Chief Medical Officer.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Chief Medical Officer Saggar Rajeev sold 9,218 shares of Liquidia Corp for $262,528.64 in a Form 4 filing.

Expected impact

likely modest pressure as the market prices in the insider sell.

Evidence & confidence

The sale size is modest relative to market cap, but insider disposals can be viewed negatively by investors.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are common and not sector-wide.

Regional

No significant regional effect.

Global

Limited to investors tracking Liquidia Corp.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing and not indicative of negative fundamentals.

Key entities

  • Company
    Liquidia Corp

    US-listed biotech company (ticker LQDA).

  • Individual
    Saggar Rajeev

    Chief Medical Officer of Liquidia Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

zacks.com
$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

investing.com
$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

finance.yahoo.com
$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.

finance.yahoo.com